The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

While Trump’s executive order provides substantial power to Elon Musk’s DOGE effort, it’s not specifically targeted to health agencies like the FDA.

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

JuliaHub simplifies complex pharmaceutical workflows by integrating analytics such as modeling and simulation in pharmacometrics. Unlike fragmented systems, it ensures seamless transitions between ...